We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going to take a look at where Tevogen Bio Holdings Inc. (NASDAQ:TVGN) stands against other AI companies under $2 billion market cap.
It’s clear that AI holds immense promise but it comes with significant risks. Some of the concerns that the market has include overreliance on a few key players, shifts in demand toward smaller competitors, and the broader impact of AI-driven market trends on earnings and valuations. While AI offers opportunities, managing risks such as customer concentration, economic headwinds, and market volatility will be crucial for its sustainable growth and integration.
Navigating AI Expectations and Market Dynamics
On CNBC ‘Fast Money,’ a discussion between traders highlighted concerns about elevated expectations for AI, especially in the chip market, with NVDA as a prime example. Past patterns in the semiconductor giant’s stock suggest potential declines, with customer concentration being a significant risk. Some believe demand for high-end chips could shift to smaller semiconductor companies. They also discussed that broader market performance might improve as other sectors gain traction, especially during earnings season, which is expected to influence investor sentiment more than AI and GLP-1 trends.
They mentioned that the key risks for earnings include the strong U.S. dollar, rising rates, and policy uncertainties, which may impact large-cap companies. While recent PPI data offered some relief, the bond market remains firm, with 10-year yields approaching 5%. Expectations for CPI and PCE figures are mixed, with potential reacceleration seen as a headwind for markets in a higher rate environment. Earnings and economic data were considered critical factors to watch by the traders.
Our Methodology
For this article, we scoured our database as well as several ETFs and media reports to find all possible AI stocks under $2 billion. We then listed the stocks in ascending order of their market cap. We also added the hedge fund sentiment around each stock which was taken from Insider Monkey’s database of 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Sergey Nivens/Shutterstock.com
Tevogen Bio Holdings Inc. (NASDAQ:TVGN)
Market Capitalization: $213.56 Million
Number of Hedge Fund Holders: 10
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is a clinical-stage immunotherapy company focused on developing precision T-cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases, cancers, and neurological disorders. The company aims to address unmet medical needs with off-the-shelf, genetically unmodified therapies. The company is revolutionizing AI in the biopharma industry. Tevogen has shown positive safety data in its clinical trials and owns significant intellectual property, including patents related to AI, which support its innovations in immunotherapy and patient accessibility.
In December 2024, Tevogen Bio (NASDAQ:TVGN) filed for a new patent titled “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models,” expanding its intellectual property portfolio. The company launched Tevogen.AI in October 2023 to accelerate drug discovery, development, manufacturing, and patient access, benefiting both its own efforts and other biotech companies.
In May 2024, the company partnered with Microsoft through the Microsoft for Startups program, gaining access to AI expertise and resources. By November 2024, AI-driven machine learning had contributed to target identification for Human Papilloma Virus, marking the beginning of Tevogen Bio’s oncology treatment pipeline. CEO Dr. Ryan Saadi, commented:
“When combining our expertise across biopharma and artificial intelligence, we anticipate becoming a leader in the field with breakthroughs to follow.”
Overall, TVGN ranks 33rd on our list of AI companies under $2 billion market cap. While we acknowledge the potential of TVGN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TVGN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center